D
David R. Gandara
Researcher at University of California, Davis
Publications - 725
Citations - 45633
David R. Gandara is an academic researcher from University of California, Davis. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 84, co-authored 685 publications receiving 40321 citations. Previous affiliations of David R. Gandara include National Institutes of Health & University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
Disease Control Rate at 8 Weeks Predicts Subsequent Survival in Platinum-Treated Extensive Stage Small-Cell Lung Cancer: Results From the Southwest Oncology Group (SWOG) Database
Primo N. Lara,James Moon,Mary W. Redman,Thomas J. Semrad,Karen Kelly,Jeffrey Warren Allen,Barbara J. Gitlitz,Philip C. Mack,David R. Gandara +8 more
TL;DR: In this large second- and third-line ES-SCLC database, DCR at 8 weeks was found to be a significant predictor of subsequent survival in patients receiving investigational therapy, with critical implications in the selection of surrogate end points in future prospective ES- SCLC trials.
Journal ArticleDOI
A phase II second-line study of pemetrexed (pem) in combination with bevacizumab (bev) in patients with advanced non-small cell lung cancer (NSCLC): An NCCTG and SWOG study
Araba A. Adjei,Sumithra J. Mandrekar,G. K. Dy,Julian R. Molina,David R. Gandara,K. L. Allen Ziegler,P. J. Stella,Kendrith M. Rowland,S. R. Schild,Ralph Zinner +9 more
TL;DR: This phase II study was performed to evaluate the clinical efficacy and toxicity of pem (500 mg/m2 iv) combined with bev (15mg/kg iv) given every 3 weeks in the 2nd-line therapy of patients with multiple sclerosis.
Journal ArticleDOI
SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer and Impaired Performance Status as Selected by a Serum Proteomics Assay.
Primo N. Lara,James C. Moon,Paul J. Hesketh,Mary W. Redman,Stephen K. Williamson,Wallace Akerley,Fred R. Hirsch,Philip C. Mack,David R. Gandara +8 more
TL;DR: In a proteomics‐enriched cohort of patients with NSCLC and PS2, pharmacodynamically separated erlotinib plus chemotherapy had better efficacy than did erlot inib alone and surpassed the protocol‐specified benchmark of PFS of at least 3 months required for further study.
Journal ArticleDOI
S1507: Phase II study of docetaxel and trametinib in patients with G12C or non-G12C KRAS mutation positive (+) recurrent non-small cell lung cancer (NSCLC).
Shirish M. Gadgeel,Jieling Miao,Jonathan W. Riess,Philip C. Mack,Gregory James Gerstner,Timothy F. Burns,Asma Taj,Wallace Akerley,Konstantin H. Dragnev,James C. Moon,David R. Gandara,Karen Kelly +11 more
TL;DR: This data indicates that KRAS+ NSCLC remains the most common genetically defined subset ofNSCLC and that MEK inhibitors have failed to provide meaningful clinical benefit both in patients and in the clinic.
Journal Article
Identification of F-box/LLR-repeated protein 17 as potential useful biomarker for breast cancer therapy.
Gary Guishan Xiao,Bing Sen Zhou,George Somlo,Jana Portnow,Agnes Juhasz,Frank Un,Helen K. Chew,David R. Gandara,Yun Yen +8 more
TL;DR: Validation of this protein using real-time RT-PCR indicates the F-box protein 17 (FBXL17) can serve as a therapeutic target and surrogate marker for breast cancer therapy.